What Ambrx Biopharma, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| O'Connor Daniel | President and CEO | Mar 07 | Disposition to Issuer · D | −48,202 | — | — | 0 |
| Nelson Sonja | Chief Financial Officer | Mar 07 | Disposition to Issuer · D | −22,936 | — | — | 0 |
| O'Connor Daniel | President and CEO | Dec 11 | Grant / award · A | +750,000 | — | — | 1,363,332 |
| Aromando Andrew | Chief Operating Officer | Dec 11 | Grant / award · A | +100,000 | — | — | 109,263 |
| Nelson Sonja | Chief Financial Officer | Dec 11 | Grant / award · A | +50,000 | — | — | 545,776 |
| O'Connor Daniel | President and CEO | Oct 27 | Open-market sale · S | −50,012 | $9.82 | −$491K | 342,845 |
| Nelson Sonja | Chief Financial Officer | Oct 27 | Open-market sale · S | −12,778 | $9.82 | −$125K | 130,079 |
| Cormorant Asset Management, Lp | 10% owner | Oct 23 | Open-market buy · P | +1,307,311 | $6.99 | +$9.14M | 11,231,000 |
Loading...
